Skip to main content

Advertisement

ADVERTISEMENT

Poster CIO 2020-22

CIO 2020-22 Durvalumab±Bevacizumab As Adjuvant Therapy In HCC At Risk Of Recurrence After Curative Therapy: EMERALD-2

R. Lencioni, J. Knox, A.-L. Cheng, S. Cleary, P. Galle, N. Kokudo, J.-W. Park, J. Zhou, P. He, S. Morgan, G. Cohen, J. Fan

This browser does not support PDFs. Please download the PDF to view it: Download PDF.

Advertisement

Advertisement

Advertisement